 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Expectations are growing that Samsung Biologics will report stronger-than-expected Q3 results, leading several securities firms to raise their target prices into the 1.2 million won range.
On October 9, KB Securities raised its target price for Samsung Biologics by approximately 15%, from 1.1 million won to 1.26 million won, in a Q3 preview report. Daishin Securities increased its target by around 20%, from 1 million won to 1.2 million won, and Hana Securities raised its target by 10%, from 1.05 million won to 1.15 million won. Both IM Securities and NH Investment & Securities maintained their previous targets of 1.15 million won and 1.2 million won, respectively.
The key driver behind the upward revisions is the full operation of Samsung Biologics' 4th plant, which has a capacity of 240,000 liters, alongside a favorable USD/KRW exchange rate. The plant, which began partial operation (60,000 liters) in October 2022, expanded to full capacity (240,000 liters) by June 2023. Typically, revenue is fully reflected about one year after a plant becomes fully operational.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
